Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...
In The Lancet in 1971, Julian Tudor Hart gave medicine one of its most important insights: the availability of medical care ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...
1 Centre for Translational Neuroscience and Mental Health, School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia 2 Department of Physical Medicine and ...
Leslie Kramer is a writer for Institutional Investor, correspondent for CNBC, journalist for Investopedia, and managing editor for Markets Group. Robert Kelly is managing director of XTS Energy LLC, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results